| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 12, 2020Global bleeding disorders community will connect and discuss treatment advances June 14-19, 2020
KING OF PRUSSIA, Pa - June 12 2020 - Global biotherapeutics leader CSL Behring announced today that the company will both attend and sponsor the World Federation of Hemophilia (WFH) first ever...
-
Jun 8, 2020Investigational Monoclonal Antibody Granted U.S. FDA Orphan Drug Designation
HATTERSHEIM, Germany – 8 June 2020 – CSL Behring, a global biotherapeutics leader, today announced results of a Phase 2 clinical trial for garadacimab (previously known as CSL312), an...
-
Jun 8, 2020• Builds on CSL Behring’s promise and commitment to the transplant community
KING OF PRUSSIA, Pa. – 8 June 2020 – Global biotherapeutics leader CSL Behring announced today that it has agreed to acquire Vitaeris Inc., a clinical-stage biotechnology company focused on...
Jun 2, 2020Initially, the alliance will develop treatment options for patients with two rare, life-threatening primary immunodeficiency diseases -- Wiskott-Aldrich Syndrome (WAS) and X-linked Agammaglobulinemia (XLA)SEATTLE and KING of PRUSSIA, Pa. – June 02, 2020 - Seattle Children’s Research Institute, one of the top pediatric research institutions in the world, and global biotechnology leader CSL...
-
May 27, 2020Thermo Fisher Scientific Inc. and CSL Limited have entered into a strategic partnership to help meet the growing demand for biologic therapies while also accelerating CSL’s broader manufacturing objectives.
WALTHAM, Mass. and KING OF PRUSSIA, Penn. 27 May 2020 Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and global biotechnology company, CSL Limited...
-
May 26, 2020“The Fight Is In Us” Campaign Seeks to Mobilize COVID-19 Survivors to Accelerate the Development of Potentially Lifesaving Therapies
Redmond, Wash., USA, and New York 26 May 2020 A coalition of world-leading medical and research institutions, blood centers, life science companies, technology companies, philanthropic...
-
May 7, 2020- Rapidly expanding support for the Alliance is increasing donations of convalescent plasma to begin clinical production, while NIH collaboration confirms clinical trial approach
Osaka, JAPAN, and King of Prussia, PA, USA – 7 May 2020 – The CoVIg-19 Plasma Alliance, an unprecedented plasma industry collaboration recently established to accelerate the development of a...
-
Apr 21, 2020Study examined the safety and tolerability of faster infusion rates and higher infusion volumes, as well as the feasibility of a new manual push administration method
PHILADELPHIA, PA – April 21, 2020 – Global biotherapeutics leader CSL Behring today announced that a clinical study examining faster infusion rates and higher volumes than currently approved...
-
Apr 8, 2020COVID-19 treatment candidate, a high-potency immunotherapy delivering human polyclonal antibodies targeted to SARS-CoV-2, generated from SAB’s novel platform technology, on-track for clinical evaluation as early as summer
King of Prussia, Pa. and Sioux Falls, S.D. 08 Apr 2020 Global biotherapeutics leader, CSL Behring and innovative human antibody development company SAB Biotherapeutics (SAB) announced today their...
-
Apr 6, 2020Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19
Osaka, JAPAN, and King of Prussia, PA, USA 06 Apr 2020 Biotest, BPL, LFB, and Octapharma have joined an alliance formed by CSL Behring (ASX:CSL/USOTC:CSLLY) and Takeda Pharmaceutical Company...
-
Feb 13, 2020Universities awarded $250,000 research grants as part of the CSL Behring-Science Center Research Acceleration Initiative
Universities awarded $250,000 research grants as part of the CSL Behring-Science Center Research Acceleration Initiative 13 Feb 2020 PHILADELPHIA – February 13, 2020 – Researchers at the...
-
Feb 11, 2020CSL Behring advances Ig clinical trial program to address unmet need in treating serious autoimmune disease
KING OF PRUSSIA, Pa.– February 11, 2020 – Global biotherapeutics leader CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted Privigen® (Immune Globulin...
-
Jan 21, 2020This year’s rankings based on independent survey of more than 60,000 U.S. employees across industries
KING OF PRUSSIA, Pa., 21 January 2020 – Forbes Magazine today named CSL Behring among its Best Employers for Diversity 2020. The annual rankings, which measure diversity across six different...
-
Jan 10, 2020
Melbourne, Australia 10 Jan 2020 Melbourne researchers have determined the molecular basis for how an important component of the immune system, called gamma-delta T cells, detects infections and...
-
Jan 9, 2020Chief Executive Officer and Managing Director Paul Perreault will present the company's overview on Monday, January 13, at 3:30 p.m. PT, (6:30 p.m. ET), at the Westin St. Francis Hotel.
King of Prussia, Pa. 09 Jan 2020 Global biotechnology giant CSL Limited, parent company of biotherapeutics leader CSL Behring and world-leading influenza provider Seqirus, will present at the 38th...
-
Dec 9, 2019First and only subcutaneous immunoglobulin (SCIg) approved for maintenance therapy in CIDP qualifies for marketing exclusivity
KING OF PRUSSIA, Pa.– December 9, 2019 – Global biotherapeutics leader CSL Behring announced today that Hizentra received orphan-drug exclusivity from the U.S. Food and Drug Administration...
-
Dec 4, 2019Unique portfolio mix of plasma, cell and gene therapy, recombinant proteins and antibody assets highlighted at Research & Development Briefing
Sydney, Australia 04 Dec 2019 CSL Limited (ASX:CSL; USOTC:CSLLY) is steadily advancing its Research & Development (R&D) pipeline and capabilities to deliver a highly differentiated product...
-
Oct 23, 2019Top 100 CEO rankings based on financial performance as well as environmental, social, and governance (ESG) ratings
KING OF PRUSSIA, Pa. – 23 October 2019 – Harvard Business Review (HBR) today named CSL Limited CEO and Managing Director Paul Perreault among the Top 100 Best Performing CEOs in the world for...
-
Sep 27, 2019• Focuses on Patients Through Disease Awareness Support Activities
MADRID, Spain – 27 September 2019 – Global biotherapeutics leader CSL Behring will host a patient-focused symposium about Alpha 1 Antitrypsin Deficiency (AATD) on Monday, 30 September, during the
-
Jul 1, 2019- Novel real world evidence for AFSTYLA® [Antihemophilic Factor (Recombinant), Single Chain] and IDELVION® ® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein] to be highlighted
Melbourne, Australia - 1 July 2019 - Global biotherapeutics leader CSL Behring announced today that the company will support the presentation of new data from its recombinant coagulation factor...
-
Jun 20, 2019Genoa, Italy
- Eight posters including one oral presentation support ongoing research and clinical experience with Hizentra®, the first and only subcutaneous immunoglobulin (Ig) therapy approved to address...
-
May 16, 2019Recipients from the US and Netherlands will be recognized in Marburg, Germany on Friday, 24 May
16 May 2019 Marburg, Germany - 16 May 2019 - Global biotherapeutics leader CSL Behring today announced that the company has named five recipients of the 2019 Professor Heimburger Award for...
-
May 15, 2019Dr. McKenzie will be accountable for leading CSL’s global end-to-end supply chain organization and its accompanying strategy.
15 May 2019 KING OF PRUSSIA, PA – May 15, 2019 - CSL today named Dr. Paul McKenzie, an accomplished global leader with diverse biotechnology experience, as Chief Operating Officer (COO),...
-
Apr 25, 2019New vial options deliver on CSL Behring’s heritage of innovation by providing more alternatives to patients
25 Apr 2019 KING OF PRUSSIA, Pa. – 25 April 2019 – Global biotherapeutics leader CSL Behring today announced that the US Food and Drug Administration (FDA) has approved 4- and 5-gram vial...
-
Apr 9, 2019Leading global biotech company brings innovative therapies for life-threatening medical conditions to UAE
Dubai, UAE - 9 April, 2019 – CSL Behring, a global biotherapeutics leader, has inaugurated its regional headquarters at Dubai Science Park (DSP), a holistic science-focused business community...